Chemical Works Of Gedeon Richter Plc · BET:RICHTER
Chemical Works Of Gedeon Richter — Richter Group — Q1 2022 Earnings Presentation
20 slides from Chemical Works Of Gedeon Richter's earnings presentation, May 10, 2022
Slide 1: Richter Group Report, Q1 2022
Richter Group Report, Q1 2022 Budapest, 10 May 2022
Slide 2: Russian–Ukrainian conflict: Extraordinary events I.
Report, Q1 2022 Russian – Ukrainian conflict Extraordinary events I. • Responsibility ‒ Safe and sustainable supply of medicines to patients ‒ Humanitarian relief granted to those in need and population at large • Ukraine ‒ Commercial operations disrupted at the end of February of 2022 ‒ Richter kep
Slide 3: Russian–Ukrainian conflict: Extraordinary events II.
Report, Q1 2022 Russian – Ukrainian conflict Extraordinary events II. • Social responsibility of Richter to support Ukrainian population ‒ HUF 10m – Charity Service of the Order of Malta ‒ HUF 10m – initiative „It’s Good to Be Good” Exceeding ‒ Humanitarian drug donation HUF 70m ‒ Drug donation to U
Slide 4: Highlights I.
Report, Q1 2022 Highlights I. 168,057 HUFm 57.1% Consolidated Gross margin sales +19.3% 22.3% 199 HUF Operating margin EPS +37.2% 37,054 HUFm Net profit* +37.8% * Net income attributable to owners of the parent. 4
Slide 5: Highlights II.
Report, Q1 2022 Central Nervous System Highlights II. 11 March 2022 – R+D agreement Richter and AbbVie announced a new co-development and licence agreement to research, develop and commercialise novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases. The collabor
Slide 6: Share Ownership Structure
Report, Q1 2022 Share Ownership Structure Corporate matters 31 March 2022 Domestic investors 11% 64% International investors Maecenas Universitatis 10% Corvini Foundation 10% Mathias Corvinus 5% Collegium Foundation Foundation for National Health and Education of Medical Doctors 6
Slide 7: Reconciliation of consolidated sales by segments
Report, Q1 2022 HUFm Increase Decrease Total Reconciliation of consolidates sales by segments (HUFm) The pharma segment accounts for 81% of consolidated turnover. The share of sales in Pharma segment increased within the Group. Exchange rate loss at consolidated sales level: HUF 1,578m 7
Slide 8: Revenue by strategic pillars
Report, Q1 2022 Revenue by strategic pillars (%) 2022 Q1 26% 12% 34% 21% 7% Branded Traditionals WHC Cariprazine Biosimilars generics 2021 Q1 29% 12% 35% 19% 5% 8
Slide 9: Change in the turnover of our selected products
Report, Q1 2022 HUFm Increase Decrease Total Change in the turnover of our selected products Turnover of Vraylar® royalty showed a robust growth of 32.1% (21.4% in USD terms) in the first quarter of 2022. Direct sales of Evra® have commenced at the end of 2021. Almost half of its turnover (47%) repo
Slide 10: Key products (1/2)
Report, Q1 2022 Key products (1/2) Cariprazine USA - Vraylar® Altogether by the end of first HUF 29,030m HUF 27,479m royalty income quarter 2022 cariprazine was (EUR 79.1m) (increase of 32.1% yoy) available in 47 countries globally. Turnover +35.1%* Submission of a supplemental New Drug Application
Slide 11: Key products (2/2)
Report, Q1 2022 Key products (2/2) Bemfola® HUF 5,772m The increase is primarily due to proceeds from WEU region. (EUR 15.7m) Nőgyógyászat +9.8% Turnover WHC Evra® Revenue split: HUF 5,291m (EUR 14.4m) Royalty income – HUF 2,818m (53%) Direct sales – HUF 2,473m (47%) Nőgyógyászat +56.9% Turnover WHC
Slide 12: Sales by geographies (%)
Report, Q1 2022 Sales by geographies (%) HUF 135.3bn Q1 2022 22% 8% 34% 23% 13% CIS Hungary Europe USA Other global +20.7% markets* Q1 2021 23% 10% 33% 22% 12% HUF 112.1bn * Including the regions of China, Latin America and Rest of the World. 12
Slide 13: Change in turnover by geographies
Report, Q1 2022 Increase Decrease HUFm Total Change in turnover by geographies In Western European region increasing proceeds of specialty products (Evra®, Terrosa® and Bemfola®) together with proceeds from contract manufacturing activities of Richter-Helm Biologics contributed the most to the subst
Slide 14: Financials – Consolidated Highlights
Report, Q1 2022 Consolidated Financials – Highlights as % of HUFbn Change % EURm total revenues Total revenue 168.1 19.3 458.1 Gross profit 96.0 22.7 261.7 57.1 Profit from operations 37.5 53.7 102.2 22.3 Profit for the period* 37.1 37.8 101.0 22.0 HUF Change % EUR EPS (diluted) 199 37.2 0.54 * Net
Slide 15: Increasing gross profit and decreasing margin
Report, Q1 2022 HUFbn Increasing 700 62% Significant increase in royalties received gross profit and 600 61% in respect of the sales of Vraylar® 60% decreasing margin 500 (HUF 6,678m) 57.1% 59% (HUFbn) 400 58% Turnover proceeds from certain 300 traditional and WHC products increased 55.5% 57% 200 56
Slide 16: S&M costs (HUFm)
Report, Q1 2022 S&M costs (HUFm) HUFm 120 000 60% 100 000 50% 80 000 40% 60 000 30% 40 000 20% 20 000 10% 0 0% 2017 2018 2019* 2020* 2021 Q1 2021 Q1 2022 S&M costs S&M percentage of sales * Reclassification of depreciation of intangible assets representing sales and other product-related licence rig
Slide 17: R&D costs (HUFm)
Report, Q1 2022 HUFm 70 000 15% R&D costs 60 000 (HUFm) 50 000 10% 40 000 30 000 5% 20 000 10 000 0 0% 2017 2018 2019 2020 2021 Q1 2021 Q1 2022 R&D costs R&D percentage of sales Split of R&D spending (%) – Q1 2022 CNS original Biosimilars WHC Branded generic research (including and traditional carip
Slide 18: Increasing operating profit and margin Q1 2022
Report, Q1 2022 Increasing operating HUFm 22.3% profit and margin 140 000 25% Significant Vraylar® royalty (HUFm) 120 000 17.3% S&M and R&D expenses increased 20% 100 000 however their proportion to turnover reduced 80 000 15% 60 000 10% Share of sales in Pharma segment increased within the Group 40
Slide 19: Reconciliation of pharma segment operating profit
Report, Q1 2022 HUFm Increase Decrease Total Reconciliation of pharma segment operating profit 19
Slide 20: Richter Gedeon
RICHTER GEDEON